DiamiR is a molecular diagnostics company focused on developing tests for early, including presymptomatic, detection, differential diagnosis, and monitoring of brain health conditions. The proprietary technology is based on targeted selection and quantitative analysis of circulating brain-enriched and inflammation-associated microRNA biomarkers in plasma. We have demonstrated detection of mild cognitive impairment with up to 96% accuracy when compared to age-matched control; prediction of progression from normal cognition to symptomatic impairment with 80% accuracy on average six years prior to clinical diagnosis; and differentiation of Alzheimer’s and other neurodegenerative diseases from control and from each other with accuracy >85%. Our lead assay, CogniMIRTM, is being developed for early detection of synaptic loss and neurodegeneration associated with Alzheimer’s disease to support more effective screening and enrollment of better characterized participants into clinical trials. Additional applications include prediction of progression (“progressors” vs “non-progressors”), detection of co-morbidities, treatment monitoring, and screening of broader populations. DiamiR collaborates with leading academic and clinical centers, disease foundations, and pharma. Our work is supported in part by SBIR grants from the National Institute on Aging of the National Institutes of Health.